Bergner Medical Consulting

The global immuno-oncology (IO) market is at a critical inflection point, with the era of single-agent PD-1/PD-L1 inhibitors giving way to multi-functional biologics. This market for bispecific antibodies (BsAbs) is projected to experience explosive growth, conservatively reaching between $15.1 bill ...

The global oncology market is at a strategic inflection point, driven by the emergence of a new class of competitors from China: BeiGene, Innovent Biologics, and Junshi Biosciences. This report provides a comprehensive, deep-dive competitive intelligence assessment and a pragmatic strategic response ...

The Antibody-Drug Conjugate (ADC) market is undergoing a profound transformation, evolving into a cornerstone of modern oncology. This explosive growth is projected to expand the market from approximately $10–$13.5 billion in 2023 to a valuation as high as $50 billion by 2030, driven by a 14-15% CAG ...

The oncology immunotherapy market is at a critical inflection point, with a total addressable market (TAM) valued at approximately $144.2 billion in 2024 and projected to exceed $247.2 billion by 2029. This growth is being reshaped by the “Subcutaneous Formulation Wars,” a defensive strategic maneuv ...

The immuno-oncology (IO) market, led by the Programmed Death-1/Ligand 1 (PD-1/PD-L1) checkpoint inhibitor class, stands at a critical juncture, defined by transformative opportunities and significant risk. The global IO market, valued between approximately $110 billion and $226 billion in 2024, is p ...

The global CAR-T cell therapy market is at a critical inflection point, with forecasts ranging from a conservative $15.97 billion to a transformative $217.6 billion by the early 2030s, contingent almost entirely on breakthrough success in solid tumors. This comprehensive report, CAR-T Evolution: Nex ...